Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

21. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation (Abstract)

Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization.Randomized control trial.Acute emergency medical admission unit in a regional teaching hospital in Hong Kong.One (...) hundred fifty adult patients with acute AF and rapid VR (>120 bpm).Patients were randomly assigned in 1:1:1 ratio to receive intravenous diltiazem, digoxin, or amiodarone for VR control.The primary end point was sustained VR control (<90 bpm) within 24 hours; the secondary end points included AF symptom improvement and length of hospitalization. At 24 hours, VR control was achieved in 119 of 150 patients (79%). The time to VR control was significantly shorter among patients in the diltiazem group (log

2009 EvidenceUpdates Controlled trial quality: uncertain

22. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials

Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

23. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation Full Text available with Trip Pro

Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF CRD summary This review compared the efficacy and safety (...) of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation. It concluded that dronedarone was less effective than amiodarone, but had fewer adverse events. Limitations in the conduct and reporting of this review mean that the estimates on which these conclusions were based may not be reliable. Authors' objectives To compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation. Searching MEDLINE was searched from inception

2009 DARE.

24. Quality of life with defibrillator therapy or amiodarone in heart failure. Full Text available with Trip Pro

Quality of life with defibrillator therapy or amiodarone in heart failure. Implantable cardioverter-defibrillator (ICD) therapy significantly prolongs life in patients at increased risk for sudden death from depressed left ventricular function. However, whether this increased longevity is accompanied by deterioration in the quality of life is unclear.In a randomized trial, we compared ICD therapy or amiodarone with state-of-the-art medical therapy alone in 2521 patients who had stable heart (...) quality of life in multiple domains. The use of amiodarone had no significant effects on the primary quality-of-life outcomes.In a large primary-prevention population with moderately symptomatic heart failure, single-lead ICD therapy was not associated with any detectable adverse quality-of-life effects during 30 months of follow-up.2008 Massachusetts Medical Society

2008 NEJM Controlled trial quality: uncertain

25. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. Full Text available with Trip Pro

Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. Amiodarone effectively suppresses atrial fibrillation but causes many adverse events.To compare major events in patients randomized to receive episodic amiodarone treatment with those who received continuous amiodarone treatment while still aiming to prevent atrial fibrillation.A randomized trial of 209 ambulatory patients with recurrent symptomatic persistent atrial (...) fibrillation, conducted from December 2002 through March 2007 at 7 Dutch medical centers.Patients were randomly assigned to receive either episodic or continuous amiodarone treatment after electrical cardioversion following amiodarone loading. Episodic amiodarone treatment was discontinued after a month of sinus rhythm and reinitiated if atrial fibrillation relapsed (1 month peri-electrical cardioversion). In the continuous treatment group amiodarone was maintained throughout.The primary end point

2008 JAMA Controlled trial quality: predicted high

26. Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery

Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

27. Prescribing amiodarone: an evidence-based review of clinical indications. Full Text available with Trip Pro

Prescribing amiodarone: an evidence-based review of clinical indications. Although amiodarone is approved by the US Food and Drug Administration only for refractory ventricular arrhythmias, it is one of the most frequently prescribed antiarrhythmic medications in the United States.To evaluate and synthesize evidence regarding optimal use of amiodarone for various arrhythmias.Systematic search of MEDLINE to identify peer-reviewed clinical trials, randomized controlled trials, meta-analyses (...) , and other studies with clinical pertinence. The search was limited to human-participant, English-language reports published between 1970 and 2007. Amiodarone was searched using the terms adverse effects, atrial fibrillation, atrial flutter, congestive heart failure, electrical storm, hypertrophic cardiomyopathy, implantable cardioverter-defibrillator, surgery, ventricular arrhythmia, ventricular fibrillation, and Wolff-Parkinson-White. Bibliographies of identified articles and guidelines from official

2007 JAMA

28. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone

Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone Caro J J, Ward A, Deniz H B, O'Brien J A, Ehreth J L Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study evaluated the economic value of an implantable cardioverter defibrillator (ICD) in comparison with amiodarone therapy for the primary prevention of sudden cardiac death in patients with heart failure, using a cost-benefit analysis. The authors

2007 NHS Economic Evaluation Database.

29. Drugs - Amiodarone

Drugs - Amiodarone Amiodarone AMO Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Pre-filled syringe containing 300 milligrams amiodarone in 10ml. ACTIONS Class 3 antiarrhythmic, lengthens cardiac action potential & therefore effective refractory period and QT interval on ECG. Blocks potassium channels in cardiac muscle. Signi?cant sodium channel blocking activity. INDICATIONS Ventricular ?brillation (VF) or pulseless ventricular tachycardia (VT) refractory to de?brillating shocks. CONTRA

2007 Joint Royal Colleges Ambulance Liaison Committee

30. An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure Full Text available with Trip Pro

An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure Article Text Therapeutics An implantable cardioverter

2006 Evidence-Based Medicine

31. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. Full Text available with Trip Pro

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. Implantable cardioverter defibrillator (ICD) therapy is effective but is associated with high-voltage shocks that are painful.To determine whether amiodarone plus beta-blocker or sotalol are better than beta-blocker alone for prevention of ICD shocks.A randomized controlled trial with blinded adjudication of events (...) of 412 patients from 39 outpatient ICD clinical centers located in Canada, Germany, United States, England, Sweden, and Austria, conducted from January 13, 2001, to September 28, 2004. Patients were eligible if they had received an ICD within 21 days for inducible or spontaneously occurring ventricular tachycardia or fibrillation.Patients were randomized to treatment for 1 year with amiodarone plus beta-blocker, sotalol alone, or beta-blocker alone.Primary outcome was ICD shock for any reason.Shocks

2006 JAMA Controlled trial quality: predicted high

32. Amiodarone

Amiodarone Amiodarone AMO Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Pre-filled syringe containing 300 milligrams amiodarone in 10ml. ACTIONS Class 3 antiarrhythmic, lengthens cardiac action potential & therefore effective refractory period and QT interval on ECG. Blocks potassium channels in cardiac muscle. Signi?cant sodium channel blocking activity. INDICATIONS Ventricular ?brillation (VF) or pulseless ventricular tachycardia (VT) refractory to de?brillating shocks. CONTRA-INDICATIONS

2006 Joint Royal Colleges Ambulance Liaison Committee

33. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. Full Text available with Trip Pro

Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. Atrial tachyarrhythmias after cardiac surgery are associated with adverse outcomes and increased costs. Previous trials of amiodarone prophylaxis, while promising, were relatively small and yielded conflicting results.To determine whether a brief perioperative course of oral amiodarone is an effective and safe prophylaxis (...) for atrial tachyarrhythmias after cardiac surgery overall and in important subgroups.Double-blind randomized controlled trial of 601 patients listed for nonemergent coronary artery bypass graft (CABG) surgery and/or valve replacement/repair surgery between February 1, 1999, and September 26, 2003, at a tertiary care hospital. The patients were followed up for 1 year.Oral amiodarone (10 mg/kg daily) or placebo administered 6 days prior to surgery through 6 days after surgery (13 days). Randomization

2005 JAMA Controlled trial quality: predicted high

34. Amiodarone versus sotalol for atrial fibrillation. (Abstract)

Amiodarone versus sotalol for atrial fibrillation. The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial.In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4.5 years. The primary end point was the time (...) to recurrence of atrial fibrillation beginning on day 28, determined by means of weekly transtelephonic monitoring.Spontaneous conversion occurred in 27.1 percent of the amiodarone group, 24.2 percent of the sotalol group, and 0.8 percent of the placebo group, and direct-current cardioversion failed in 27.7 percent, 26.5 percent, and 32.1 percent, respectively. The median times to a recurrence of atrial fibrillation were 487 days in the amiodarone group, 74 days in the sotalol group, and 6 days

2005 NEJM Controlled trial quality: predicted high

35. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. Full Text available with Trip Pro

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. Sudden death from cardiac causes remains a leading cause of death among patients with congestive heart failure (CHF). Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD) has been proposed to improve the prognosis in such patients.We randomly assigned 2521 patients with New York Heart Association (NYHA) class II or III CHF and a left ventricular ejection fraction (LVEF) of 35 percent (...) or less to conventional therapy for CHF plus placebo (847 patients), conventional therapy plus amiodarone (845 patients), or conventional therapy plus a conservatively programmed, shock-only, single-lead ICD (829 patients). Placebo and amiodarone were administered in a double-blind fashion. The primary end point was death from any cause.The median LVEF in patients was 25 percent; 70 percent were in NYHA class II, and 30 percent were in class III CHF. The cause of CHF was ischemic in 52 percent

2005 NEJM Controlled trial quality: predicted high

36. Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis

Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis Aasbo J D, Lawrence A T, Krishnan K, Kim M H, Trohman R G CRD summary The authors assessed the use of prophylactic amiodarone given around (...) the time of cardiac surgery. They found that the incidence of atrial fibrillation or flutter, ventricular tachycardia or fibrillation, and stroke were reduced by amiodarone. Length of hospital stay was also reduced, but there was no difference in death rates. The review was well conducted and the results appear reliable. Authors' objectives To assess whether prophylactic amiodarone decreases the incidence of major cardiovascular morbidity, length of hospital stay and mortality after cardiac surgery

2005 DARE.

37. Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery

Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Reddy P, Kalus J S, Caron M F, Horowitz (...) compared. The alternative strategies were amiodarone, pacing, amiodarone plus pacing, and placebo. Patients received a loading dose of amiodarone (1,050 mg intravenously) within 6 hours after surgery, followed by oral amiodarone (400 mg 3 times daily) or matching placebo on postoperative days 1 to 4. Atrial septic pacing consisted of the use of a single pacing wire and one pacemaker box. It was started within 6 hours after surgery and was continued for 96 hours. Type of intervention Secondary

2004 NHS Economic Evaluation Database.

38. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis

Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P CRD summary This well reported review compared amiodarone with placebo (...) or class Ic drugs for the cardioversion of recent-onset atrial fibrillation (AF). Even though the onset of conversion was delayed, the efficacy of amiodarone was similar at 24 hours compared with class Ic drugs. The conclusions reached by the authors seem valid and the limited generalisability of the findings was acknowledged. Authors' objectives To conduct a meta-analysis comparing amiodarone with placebo or class Ic drugs for the cardioversion of recent-onset atrial fibrillation (AF). Searching

2003 DARE.

39. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis

Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

40. Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT

Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia (...) - AMIOVIRT Strickberger S A, Hummel J D, Bartlett T G, Frumin H I, Schuger C D, Beau S L, Bitar C, Morady F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of amiodarone with an implantable cardioverter

2003 NHS Economic Evaluation Database.